Skip to main content
NCBI home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1987 May;71(5):387–390. doi: 10.1136/bjo.71.5.387

Short term cyclosporin A treatment of Behçet's disease.

A U Müftüoğlu, H Pazarli, S Yurdakul, H Yazici, B Y Ulkü, Y Tüzün, S Serdaroğlu, E Altuğ, H Bahçecioğlu, G Güngen
PMCID: PMC1041174  PMID: 3580358

Abstract

Eleven separate three-month courses of cyclosporin A, an oral solution 10 mg/kg/day, were administered to eight patients with Behçet's disease with sight-threatening posterior uveitis. It was found to be effective in arresting the inflammatory activity in the eye as well as the mucocutaneous lesions of Behçet's disease. Improvement in visual acuity was observed within one week of starting therapy. Severe exacerbations in the ocular and mucocutaneous lesions occurred on withdrawal of the drug. At this dosage side effects included hirsutism in all women, and a slight rise of serum bilirubins in two patients and of blood urea in one patient. The latter two conditions responded rapidly to dose adjustment.

Full text

PDF
387

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrus L., Lafferty K. J. Inhibition of T-cell activity by cyclosporin A. Scand J Immunol. 1981 May;15(5):449–458. doi: 10.1111/j.1365-3083.1982.tb00670.x. [DOI] [PubMed] [Google Scholar]
  2. Bunjes D., Hardt C., Röllinghoff M., Wagner H. Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur J Immunol. 1981 Aug;11(8):657–661. doi: 10.1002/eji.1830110812. [DOI] [PubMed] [Google Scholar]
  3. Kalbian V. V., Challis M. T. Behçet's disease. Report of twelve cases with three manifesting as papilledema. Am J Med. 1970 Dec;49(6):823–829. doi: 10.1016/s0002-9343(70)80064-x. [DOI] [PubMed] [Google Scholar]
  4. Nussenblatt R. B., Gery I., Ballintine E. J., Wacker W. B. Cellular immune responsiveness of uveitis patients to retinal S-antigen. Am J Ophthalmol. 1980 Feb;89(2):173–179. doi: 10.1016/0002-9394(80)90108-7. [DOI] [PubMed] [Google Scholar]
  5. Nussenblatt R. B., Palestine A. G., Chan C. C. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol. 1983 Sep;96(3):275–282. doi: 10.1016/s0002-9394(14)77814-6. [DOI] [PubMed] [Google Scholar]
  6. Nussenblatt R. B., Palestine A. G., Rook A. H., Scher I., Wacker W. B., Gery I. Treatment of intraocular inflammatory disease with cyclosporin A. Lancet. 1983 Jul 30;2(8344):235–238. doi: 10.1016/s0140-6736(83)90230-1. [DOI] [PubMed] [Google Scholar]
  7. O'Duffy J. D., Lehner T., Barnes C. G. Summary of the Third International Conference on Behçet's Disease, Tokyo, Japan, October 23-24, 1981. J Rheumatol. 1983 Feb;10(1):154–158. [PubMed] [Google Scholar]
  8. STRACHAN R. W., WIGZELL F. W. Polyarthritis in Behcet's multiple symptom complex. Ann Rheum Dis. 1963 Jan;22:26–35. doi: 10.1136/ard.22.1.26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. White D. J. Cyclosporin A. Clinical pharmacology and therapeutic potential. Drugs. 1982 Oct;24(4):322–334. doi: 10.2165/00003495-198224040-00004. [DOI] [PubMed] [Google Scholar]
  10. Yazici H., Tuzun Y., Pazarli H., Yalcin B., Yurdakul S., Muftuoglu A. The combined use of HLA-B5 and the pathergy test as diagnostic markers of Behçet's disease in Turkey. J Rheumatol. 1980 Mar-Apr;7(2):206–210. [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES